D&D Pharmatech Inc. (KOSDAQ:347850)
South Korea
· Delayed Price · Currency is KRW 48,150
+2,200 (4.79%)
Apr 1, 2025, 3:30 PM KST
D&D Pharmatech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 11,437 | 18,677 | 610.57 | 1,364 | - | Upgrade
|
| Revenue Growth (YoY) | -38.77% | 2958.97% | -55.24% | - | - | Upgrade
|
| Cost of Revenue | 19.67 | 21.35 | 31.36 | 26.09 | 43.06 | Upgrade
|
| Gross Profit | 11,417 | 18,656 | 579.21 | 1,338 | -43.06 | Upgrade
|
| Selling, General & Admin | 8,126 | 8,427 | 9,287 | 8,823 | 7,353 | Upgrade
|
| Research & Development | 23,291 | 19,973 | 47,125 | 56,826 | 50,805 | Upgrade
|
| Other Operating Expenses | 365.69 | 336.28 | 266.34 | 304.96 | 211.49 | Upgrade
|
| Operating Expenses | 36,434 | 32,142 | 69,232 | 77,015 | 69,064 | Upgrade
|
| Operating Income | -25,017 | -13,486 | -68,653 | -75,677 | -69,107 | Upgrade
|
| Interest Expense | -614.83 | -1,427 | -2,959 | -1,012 | -5,712 | Upgrade
|
| Interest & Investment Income | 1,114 | 570.24 | 729.08 | 259.37 | 806.81 | Upgrade
|
| Earnings From Equity Investments | 3,606 | -1,787 | -9,148 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 579.45 | 405.96 | -670.81 | 244.8 | 171.16 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,060 | 15,721 | 15,387 | 4,137 | 6,824 | Upgrade
|
| EBT Excluding Unusual Items | -19,272 | -2.36 | -65,315 | -72,047 | -67,017 | Upgrade
|
| Impairment of Goodwill | - | - | -27,421 | - | -494.42 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,767 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -118.38 | -84.78 | 21,524 | - | - | Upgrade
|
| Asset Writedown | -9,199 | 4,582 | -92,301 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 515.65 | Upgrade
|
| Pretax Income | -30,357 | 4,494 | -163,513 | -72,047 | -66,995 | Upgrade
|
| Income Tax Expense | -873.72 | 1,068 | -26,487 | -2,185 | -2,711 | Upgrade
|
| Earnings From Continuing Operations | -29,483 | 3,427 | -137,025 | -69,862 | -64,284 | Upgrade
|
| Minority Interest in Earnings | 860.63 | 507.26 | 958.94 | 1,638 | 878.08 | Upgrade
|
| Net Income | -28,623 | 3,934 | -136,067 | -68,224 | -63,406 | Upgrade
|
| Net Income to Common | -28,623 | 3,934 | -136,067 | -68,224 | -63,406 | Upgrade
|
| Shares Outstanding (Basic) | 10 | 9 | 8 | 8 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 9 | 8 | 8 | 7 | Upgrade
|
| Shares Change (YoY) | 13.66% | 10.67% | -2.05% | 12.66% | 118.38% | Upgrade
|
| EPS (Basic) | -2823.00 | 441.00 | -16881.58 | -8483.33 | -9097.20 | Upgrade
|
| EPS (Diluted) | -2823.00 | 441.00 | -16882.00 | -8694.64 | -9399.94 | Upgrade
|
| Free Cash Flow | -22,201 | -9,163 | -53,795 | -53,560 | -51,176 | Upgrade
|
| Free Cash Flow Per Share | -2189.61 | -1027.18 | -6674.28 | -6508.66 | -7006.11 | Upgrade
|
| Gross Margin | 99.83% | 99.89% | 94.86% | 98.09% | - | Upgrade
|
| Operating Margin | -218.74% | -72.21% | -11244.15% | -5547.71% | - | Upgrade
|
| Profit Margin | -250.27% | 21.06% | -22285.31% | -5001.38% | - | Upgrade
|
| Free Cash Flow Margin | -194.12% | -49.06% | -8810.69% | -3926.36% | - | Upgrade
|
| EBITDA | -19,490 | -9,058 | -54,914 | -63,776 | -57,764 | Upgrade
|
| EBITDA Margin | -170.42% | -48.50% | - | - | - | Upgrade
|
| D&A For EBITDA | 5,527 | 4,428 | 13,739 | 11,901 | 11,343 | Upgrade
|
| EBIT | -25,017 | -13,486 | -68,653 | -75,677 | -69,107 | Upgrade
|
| EBIT Margin | -218.74% | -72.21% | - | - | - | Upgrade
|
| Effective Tax Rate | - | 23.76% | - | - | - | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.